Geron (GERN) updates Clinical Data from GRNOPC1 Spinal Cord Injury Trial Proactive Investors USA & Canada The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. There is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, ... Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial |
